Format

Send to

Choose Destination
Nat Med. 2019 Mar;25(3):526-528. doi: 10.1038/s41591-018-0220-6.

Author Correction: Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo.

Author information

1
Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.
2
Cellular & Molecular Physiology, Yale University School of Medicine, New Haven, CT, USA.
3
Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT, USA.
4
Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China.
5
St. Vincent's Institute of Medical Research and Department of Medicine, University of Melbourne & Mary MacKillop Institute for Health Research, Australian Catholic University Fitzroy, Fitzroy, Victoria, Australia.
6
Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
7
Department of Medicine, Yale University School of Medicine, New Haven, CT, USA. gerald.shulman@yale.edu.
8
Cellular & Molecular Physiology, Yale University School of Medicine, New Haven, CT, USA. gerald.shulman@yale.edu.
9
Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT, USA. gerald.shulman@yale.edu.

Abstract

In the version of this article originally published, the VPC and VCS flux data shown in Fig. 6e,f were inadvertently duplicated from Fig. 5j,k. The correct data are now shown in Fig. 6e,f. In these corrected data, VPC flux in response to chronic oral metformin treatment was still significantly decreased (Fig. 6e), and there was still no impact of metformin on VCS flux (Fig. 6f). Therefore, the text describing these data remains the same and this correction does not change the conclusion of this study.

PMID:
30733621
DOI:
10.1038/s41591-018-0220-6

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center